Trends in breast cancer among elderly women: Development in estrogen and HER2 subtypes in the last ten years

IF 7.9 2区 医学 Q1 OBSTETRICS & GYNECOLOGY Breast Pub Date : 2025-02-01 DOI:10.1016/j.breast.2024.103860
Frederik K. Palshof , Lina S. Mørch , Maj-Britt R. Jensen , Hans H. Storm , Niels Kroman , Tove H.F. Tvedskov
{"title":"Trends in breast cancer among elderly women: Development in estrogen and HER2 subtypes in the last ten years","authors":"Frederik K. Palshof ,&nbsp;Lina S. Mørch ,&nbsp;Maj-Britt R. Jensen ,&nbsp;Hans H. Storm ,&nbsp;Niels Kroman ,&nbsp;Tove H.F. Tvedskov","doi":"10.1016/j.breast.2024.103860","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Increasing life expectancy increases breast cancer (BC) rates in elderly, where better health allows for improved tolerance of treatments. We assessed trends in BC incidence of tumor subtypes for women with focus on the elderly.</div></div><div><h3>Methods</h3><div>Changes in BC incidence in women by age from 2012 to 2021 were assessed using data from the Nordic countries. We calculated the incidence of BC subtypes by age group using data from the Danish Breast Cancer Group (DBCG) database. We used generalized linear models assuming a Poisson distribution.</div></div><div><h3>Results</h3><div>In the Nordic countries, 205 305 women were diagnosed with BC between 2012 and 2021. In Denmark, 50 858 BC patients were diagnosed between 2012 and 2022, identified with tumor characteristics. Incidence of BC among women aged 80+ increased significantly across the Nordic Countries, with 1.24 % per year (95 % CI: 0.07 %: 2.41 %). In Denmark, in the 80+ group, the ER+/HER2- subtype had the highest increase, with 1.98 % per year (95 % CI: 1.10 %: 2.87 %).</div></div><div><h3>Conclusion</h3><div>Across the Nordic countries, incidence of BC in women aged 80+ increased. In Denmark, rising incidence of BC is driven by the ER+/HER2- subtype in the 80+ group, which has the best prognosis and gentle treatments. More elderly BC patients will require treatment and follow-up in the future.</div></div>","PeriodicalId":9093,"journal":{"name":"Breast","volume":"79 ","pages":"Article 103860"},"PeriodicalIF":7.9000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11722930/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Breast","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0960977624001917","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Increasing life expectancy increases breast cancer (BC) rates in elderly, where better health allows for improved tolerance of treatments. We assessed trends in BC incidence of tumor subtypes for women with focus on the elderly.

Methods

Changes in BC incidence in women by age from 2012 to 2021 were assessed using data from the Nordic countries. We calculated the incidence of BC subtypes by age group using data from the Danish Breast Cancer Group (DBCG) database. We used generalized linear models assuming a Poisson distribution.

Results

In the Nordic countries, 205 305 women were diagnosed with BC between 2012 and 2021. In Denmark, 50 858 BC patients were diagnosed between 2012 and 2022, identified with tumor characteristics. Incidence of BC among women aged 80+ increased significantly across the Nordic Countries, with 1.24 % per year (95 % CI: 0.07 %: 2.41 %). In Denmark, in the 80+ group, the ER+/HER2- subtype had the highest increase, with 1.98 % per year (95 % CI: 1.10 %: 2.87 %).

Conclusion

Across the Nordic countries, incidence of BC in women aged 80+ increased. In Denmark, rising incidence of BC is driven by the ER+/HER2- subtype in the 80+ group, which has the best prognosis and gentle treatments. More elderly BC patients will require treatment and follow-up in the future.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
老年妇女乳腺癌的趋势:近十年雌激素和HER2亚型的发展
背景:预期寿命的延长增加了老年人乳腺癌(BC)发病率,老年人健康状况的改善可以提高对治疗的耐受性。我们评估了女性BC肿瘤亚型发病率的趋势,重点是老年人。方法:使用北欧国家的数据评估2012年至2021年不同年龄女性BC发病率的变化。我们使用丹麦乳腺癌组(DBCG)数据库的数据,按年龄组计算BC亚型的发病率。我们使用假定泊松分布的广义线性模型。结果:在北欧国家,2012年至2021年间,20305名女性被诊断为BC。在丹麦,2012年至2022年间诊断出50858例BC患者,确定具有肿瘤特征。在北欧国家,80岁以上女性的BC发病率显著增加,为每年1.24% (95% CI: 0.07%: 2.41%)。在丹麦,在80+组中,ER+/HER2-亚型的增加最高,每年增加1.98% (95% CI: 1.10%: 2.87%)。结论:在北欧国家,80岁以上女性的BC发病率增加。在丹麦,80岁以上人群中ER+/HER2-亚型是导致BC发病率上升的主要原因,该人群预后最好,治疗温和。更多的老年BC患者将需要治疗和随访。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Breast
Breast 医学-妇产科学
CiteScore
8.70
自引率
2.60%
发文量
165
审稿时长
59 days
期刊介绍: The Breast is an international, multidisciplinary journal for researchers and clinicians, which focuses on translational and clinical research for the advancement of breast cancer prevention, diagnosis and treatment of all stages.
期刊最新文献
Comparative validation of PREDICT versions 3.1 and 2.2 for overall survival in the Dutch breast cancer population Beyond survival: Confronting the unmet needs in oncofertility care for young women with breast cancer. Trends in local, regional and contralateral breast tumor recurrence within five years after diagnosis in the Netherlands: a population-based study including 121347 patients Secondary dry eye disease in breast cancer patients: a pilot study Adjuvant ovarian function suppression and aromatase inhibitors in premenopausal patients with hormone receptor and HER2 positive breast cancer, by timing of chemotherapy and trastuzumab and response to neoadjuvant therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1